Cogent Biosciences
COGT
26.72
-1.03
-3.70%
Cogent Biosciences
US · COGT
#2052 by market cap
Listed 2016
26.72
-1.03
-3.70%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:53
Recent news
-
Rating change
J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)TipRanks · 2026/3/14
-
Rating change
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52Market Newswire · 2026/5/7
-
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $56Market Newswire · 2026/11/9
-
Rating change
Needham Maintains Cogent Biosciences(COGT.US) With Hold RatingMarket Newswire · 2026/8/11
-
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $61Market Newswire · 2026/11/13
-
Rating change
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $52Market Newswire · 2026/8/12
-
Rating change
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR)TipRanks · 2026/6/1
-
Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/9/17
-
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/11/6
-
Rating change
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/9/16
-
Rating change
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $62Market Newswire · 2026/9/9
-
UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/10/14
-
Rating change
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $64Market Newswire · 2026/3/14
-
Rating change
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $45 to $55Market Newswire · 2026/5/6
-
Rating change
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy RatingMarket Newswire · 2026/6/1
-
Rating change
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/4/2
-
Rating change
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/9/17
-
Rating change
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52Market Newswire · 2026/4/2
-
Rating change
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $55Market Newswire · 2026/8/17
-
Rating change
Jefferies Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $55Market Newswire · 2026/3/16
-
Rating change
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT)TipRanks · 2026/3/2
-
Rating change
Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/2/19
-
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/10/27
-
Rating change
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/6/15
-
Rating change
UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/6/1
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:53:23 · For reference only, not investment advice and not tailored to your situation.
Cogent Biosciences discussion 0 comments